Novel Molecular Targets Participating in Myocardial Ischemia-Reperfusion Injury and Cardioprotection

Worldwide morbidity and mortality from acute myocardial infarction (AMI) and related heart failure remain high. While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical treatment at present, collateral myocardial ischemia-reperfusion injury (MIRI) and pe...

Full description

Saved in:
Bibliographic Details
Published inCardiology research and practice Vol. 2019; no. 2019; pp. 1 - 16
Main Authors Li, Xiao-Kang, Huang, Jing-Song, Fujino, Masayuki, Chen, Chen, Wu, Min, Liu, Nan-Bo, Zhu, Ping
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 01.01.2019
Hindawi
John Wiley & Sons, Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Worldwide morbidity and mortality from acute myocardial infarction (AMI) and related heart failure remain high. While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical treatment at present, collateral myocardial ischemia-reperfusion injury (MIRI) and pertinent cardioprotection are still challenging to address and have inadequately understood mechanisms. Therefore, unveiling the related novel molecular targets and networks participating in triggering and resisting the pathobiology of MIRI is a promising and valuable frontier. The present study specifically focuses on the recent MIRI advances that are supported by sophisticated bio-methodology in order to bring the poorly understood interrelationship among pro- and anti-MIRI participant molecules up to date, as well as to identify findings that may facilitate the further investigation of novel targets.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Academic Editor: Mariantonietta Cicoira
ISSN:2090-8016
2090-0597
2090-0597
DOI:10.1155/2019/6935147